JDS and Synthon to Co-Promote Bipolar Drug

New York's JDS Pharmaceuticals and the North Carolina-based arm of Synthon Pharmaceuticals have entered into a co-promotion agreement for Lithobid, a leading brand of twice-daily lithium carbonate for the treatment of bipolar disorder. Synthon will co-promote Lithobid through its sales force of approximately 50 sales representatives to high volume prescribing psychiatrists across the U.S. Financial terms of the agreement were not disclosed.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=4B344355-3A97-4DA6-A37B-B2C38FB42B75)